Antibody (3)
Launched (3)
Mouse (3)
- (3)
Unconjugated (3)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|---|
RSV-MY2189 | HEK293 | Monoclonal Anti-RSV(B)-Pre-F0 Antibody, Mouse IgG1 (7B2) (MALS verified) | ||||
RSV-MY2202 | HEK293 | Monoclonal Anti-RSV(B)-Pre-F0 specific Antibody, Human IgG1 (4H8) (MALS verified) | ||||
RSV-MY2246 | HEK293 | Monoclonal Anti-RSV(B)-Pre-F0 specific Antibody, Human IgG1 (8E3) (MALS verified) |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| NG-641 | EnAd-FAP-BiTE; EnAd-FAP-Tac; NG-641; NG-aFAP | Phase 1 Clinical | Akamis Bio Ltd, University Of Oxford | Squamous Cell Carcinoma of Head and Neck; Neoplasms, Glandular and Epithelial; Neoplasm Metastasis | Details |

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland



